Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders
|
|
- Philip Oliver
- 6 years ago
- Views:
Transcription
1 Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders Daniel Snyder, PhD Medical Director, Neurology North America Medical Affairs Ipsen Biopharmaceuticals, Inc. 1
2 Disclaimer I am an employee of Ipsen Biopharmaceuticals, Inc. (Ipsen). The statements or opinions expressed in this presentation are my own and do not necessarily represent those of Ipsen. 2
3 Agenda How did we get to Rules of Engagement? 1. Responding to Unsolicited Request for Off-Label Information 2. Distributing Scientific and Medical Publications on Unapproved New Uses 3. OIG Compliance Policy Guidance (CPG) for Pharmaceutical Manufacturers Where does guidance come form? When to use a MSL Responding to an unsolicited request Rules of Engagement with Commercial Sales Reimbursement Managed Markets 3
4 Legal Guidance No legal or regulatory requirement to maintain independent Medical Affairs department; only guidance documents 1. Responding to Unsolicited Requests for Off-Label Information Draft Guidance December Distributing Scientific and Medical Publications on Unapproved New Uses Recommended Practices Draft Guidance February OIG Compliance Policy Guidance (CPG) for Pharmaceutical Manufacturers May
5 Responding to Unsolicited Requests for Off-Label Information FDA Draft Guidance document December 2011 Definition of Unsolicited Request: Initiated by persons or entities that are completely independent of the relevant firm Can be non-public or public Non-public directed privately to the firm Public made in a public forum, either to the firm or to a forum at large Requests that are prompted in any way by the manufacturer are not unsolicited 5
6 Responding to Unsolicited Requests for Off-Label Information (cont.) Responses must meet the following requirements: Truthful, balanced, non-misleading, accurate; Tailored to respond to the specific question asked; Information should only be provided to the individual making the request; and If question is too broad, it should be narrowed Additional Requirements to be Included in Response: FDA-approved labeling, including important safety information; A prominent statement notifying the recipient that FDA has not approved the product as safe and effective for use in the materials provided; and A complete list of references for all information disseminated in the response Adequate records should be maintained regarding nature of request, information provided and follow-up inquiries, if any 6
7 Distributing Scientific and Medical Publications on Unapproved New Uses FDA Draft Guidance February 2014 Recommendations for manufacturers who choose to distribute scientific or medical journal articles that include unapproved/uncleared uses of its product(s) Must be published by an organization with an editorial board that uses experts who have expertise in the subject matter of the article If recommendations are followed, FDA does not intend to use distribution as evidence of intent that product(s) be used for unapproved new use 7
8 Distributing Scientific and Medical Publications on Unapproved New Uses Recommendations for Scientific Journal Articles Be peer reviewed and published in accordance with peer-review procedures of organization Be in the form of an unabridged reprint or copy Contain information that describes adequate and well-controlled clinical investigations Be disseminated with approved labeling for each of product included in article Be disseminated with a comprehensive bibliography (when it exists) of publications discussion adequate and well-controlled studies published in scientific or medical journals Be disseminated with a representative publication (when it exists) that reaches contrary or different conclusions regarding the unapproved use Be distributed separately from the delivery of information that is promotional in nature 8
9 Distributing Scientific and Medical Publications on Unapproved New Uses Other Recommendations for Scientific Articles Must not : Be false or misleading Contain information recommending or suggesting the use or product that makes it dangerous to health when used in such matter Should not : Be in a form of special supplement or publication funded by manufacturer Be marked, highlighted, summarized or characterized to emphasize or promote unapproved use Be primarily distributed by manufacturer (i.e., should be generally available publicly Be written, edited, excerpted, or published specifically for or at the request of manufacturer Be edited by manufacturer (or another 3 rd party paid by manufacturer) Be attached to specific product information, other than approved label 9
10 Distributing Scientific and Medical Publications on Unapproved New Uses Accompanying Statement Include prominently displayed and permanently affixed statement disclosing: Drug included in journal reprint which manufacturer has interest; Some or all uses of manufacturer s drug(s) described in information have not been approved or cleared by FDA; Any author known to manufacturer having a financial interest in a product included in article or is receiving compensation from manufacturer (including nature and amount), along with affiliation of author; Any person known to manufacturer who provided funding for study; and All significant risks or safety concerns associated with unapproved use(s) of product discussed in article known to manufacture, but not discussed in it 10
11 OIG Compliance Policy Guidance (CPG) for Pharmaceutical Manufacturers May 2003 Separation of sales and commercial from medical and scientific functions to reduce the risk of fraud and abuse: Educational grants; research funding Consulting Arrangements Consulting and Advisory Payments to HCPs Should comply with the PhRMA Code Failure to implement policies to minimize risk of sham arrangements increases risk of violating Federal Anti-Kickback Statute (AKS) 11
12 Where does guidance come from? Separation of Medical Affairs function is understood by government enforcement activities Three (3) Main Areas of Focus: 1. Commercial interactions with Medical Affairs 2. Advisory Boards 3. Continuing Medical Education and Educational Grants 12
13 Recent Enforcement Commercial and Medical Interactions Allegations include: Off-label promotion by Medical Affairs personnel in violation of Federal Food, Drug and Cosmetic Act (FDCA); Off-label promotion by Medical Affairs personnel used as evidence to support FCA allegations Unlawful remuneration paid by medical affairs to third parties in violation of the AKS (and thus, FCA, in some cases) 13
14 Recent Enforcement Commercial and Medical Interactions (cont.) Types of Allegations Include: MSLs rode with sales reps to answer questions on research/clinical studies to initiate off-label discussions MSLs reported indirectly to sales directors MSLs used to market product for off-label uses MSLs develop Thought Leaders who would support and promote off-label uses; support off-label publications Other Risk Areas Publications and investigator-initiated studies (IIS) Commercial involvement in funding IIS or patient recruitment Engagement of contractors to write journal articles about off-label uses 14
15 Recent Enforcement Advisory Boards Purpose of market research is to collect information from a targeted audience; should be fair discussion of information provided Disguising promotional programs as marketing research or scientific exchange is prohibited Allegations include: Programs funded through promotional budget and organized by commercial staff Sales reps select the HCPs based on how much they prescribe the product Meetings are passive with no actual feedback (thus, disguised kickbacks to physicians) 15
16 Recent Enforcement CME and Educational Grants Can provide funding for Medical Education programs as long as it is bona fide and arm s length and manufacturer does not control the content or faculty Allegations include: Funding programs for purpose of off-label promotion or providing improper remuneration to HCPs Improper influence of content of company-sponsored CME Improper control of speakers by manufacturer 16
17 When to Involve a MSL Request a MSL when... Physician Interest in Research Knowledgeable, experienced, have subjects ISS, R&D, other support Review scientific research Unsolicited requests for off-label information Requested disease state presentation Review complicated scientific material in depth Physician Education Needs Requests for specific information related to company drug Request follow-up regarding an institutional educational event (educational grant request) 17
18 How Does A Med Affairs Team Respond to Unsolicited Requests from the Customer? How do we do this? Commercial captures the question from the customer, completes the medical information request form, captures the customer signature, and submits through appropriate channel. Medical Information or and/or MSL addresses customer question. Medical Information and/or MSL informs Commercial that the case has been completed. Commercial cannot dial the hotline number or MSL on a phone and hand the phone over to the HCP. 18
19 Medical Information vs. MSL Request When to request Medical Information General requests related to company-sponsored pivotal trials outside of scope of approved promotional materials Efficacy/Safety/Dosing information/product manufacturing issues General requests related to company-sponsored non-pivotal trials outside of scope of approved promotional materials Published or data on file Publication/standard response letter requests to specific scientific/clinical question Please send studies/information that discuss the data on maximum dose of drug. If Medical Information believes the question needs more clarification or it is a complex answer, Medical Information may send request to the MSL or another pertinent department 19
20 Medical Information vs. MSL Request Continued When to request a MSL Specific requests related to a given situation, patient type or training question outside the scope of approved promotional materials (that may require a more complex answer and/or discussion) How much drug should be administered? HCP requests information from a non-company sponsored publication, medical conference, or other sources of scientifically valid/significant data outside of a journal publication that relates to one of the company s drugs Requests to discuss a research study idea (i.e., ISS) or to ask to participate in an company-sponsored clinical trial. HCP specifically requests a MSL Sales is not comfortable answering an in-depth scientific question. 20
21 Interactions between the MSL and Commercial MSL and Commercial Interactions General Principles Sales Personnel, Reimbursement Managers, the Managed Markets personnel and MSLs all have specialized non-overlapping roles but may interact with the same account or HCP that is affiliated with a specific account. It may be appropriate for members from different teams to be aware if they are meeting with a HCP or HCO that is called on by multiple field-based personnel, and share the communication style and logistic characteristics of common contacts. The fact that a visit occurred and the timing of the visit may be shared. Maintain firewall (e.g., Sales representative does not share prescription volume of an account with the MSL, and conversely, the MSL does not share subject matter or content of his/her discussion with the KOL/HCP with Sales) On an as-needed basis, MSLs may meet with Commercial field-based personnel for the purpose of clarifying on-label and disease state information the personnel were already trained on. Off-label discussions between the MSL and Commercial field-based personnel are strictly prohibited. 21
22 Interactions between the MSL and Commercial Continued Responding to Unsolicited HCP Requests for Medical Information The MSL must confirm the unsolicited request in the medical information request form with the HCP within 48 hours of receipt. The purpose of this confirmatory telephone conversation or is to ensure the MSL understands the question or request. Commercial personnel who submit a medical information request form are permitted to provide the MSL a notification that they will receive a medical information request form via (preferred) or by phone call. Only details about the HCP and their location may be provided in this communication (i.e., no details about the unsolicited question may be provided). 22
23 Interactions between the MSL and Commercial Continued Guidance on Joint Calls Sales Sales personnel and MSLs may not make joint calls with HCPs. May facilitate meet and greet opportunities in those instances where the HCP is known to one party and not the other. MSL must leave before a sales presentation or discussion; sales personnel must leave before a scientific discussion between an MSL and HCP. MSL cannot engage in a telephone conversation with an HCP while sales personnel are present. If asked by the MSL, they may indicate whether HCP is a company advocate, is neutral, or is a detractor. Reimbursement Managers (RMs) Reimbursement Managers (RMs) and MSLs may not make joint calls to individual HCPs offices. Occasionally, MSLs and RMs may attend a meeting with HCPs when it is likely both scientific and business issues will be discussed (i.e., hospital formulary discussion, advisory board or trade conference). 23
24 Interactions between the MSL and Commercial Continued Guidance on Joint Calls Continued Managed Markets Managed Markets personnel interactions with Payers (Commercial and Government), GPO, SPPs, Retailers, and Distributors may be conducted with a MSL when it is likely that discussion of both scientific and business issues will take place. MSLs may also participate in meetings with Integrated Delivery Networks (IDNs) when requested in advance by the IDN. In the event an off-label question is asked by a HCP in this setting, the MSL may respond to the unsolicited request for off-label information as directed by company policy. The Managed Markets member may remain in the room but may not engage in the off-label discussion. 24
25 Interactions between the MSL and Commercial Continued Out-Of-Office HCP Meals MSLs may attend meals provided by the Managed Markets team provided they have a legitimate reason to be part of the business discussion (i.e., a meeting that includes a clinical presentation). Sales personnel may not attend these meals. 25
26 Thank you! 26
27 Federal Anti-Kickback Statute (AKS) Prohibits a person from knowingly and willfully offering, paying, soliciting or receiving any remuneration directly or indirectly, overtly or covertly, in cash or kind to induce or reward referrals of items or services reimbursable by a Federal health care program. 42 U.S.C. 1320a- 7b(b) Remuneration is anything of value, cash or in-kind. See e.g., OIG Advisory Opinion No. 98-2, at 5 (Apr. 8, 1998) One purpose test statute is implicated if one purpose of the remuneration is to induce Federal health care program business, even if such inducement is not sole or primary purpose. See, e.g., United States v. Kats, 871 F2d. 105 (9 th Cir. 1989); United States v. Greber, 760 F.2d 68 (3d Cir. 1985), cert. denied, 474 U.S. 988 (1985) To be considered inducement, the remuneration need only be intended to influence the judgment of the recipient (no direct quid pro quo required) 27
28 False Claims Act (FCA) 31 USC 3729, et seq. Civil statute that imposes liability for knowingly: Presenting or causing to be presented a false or fraudulent claim; Making, using or causing to be made or used a false record or statement material to a false or fraudulent claim Claims resulting from a kick-back violation are false or fraudulent acts under FCA Penalties include: $5,500 to $11,000 per claim 3x damages 28
Off-Label Promotion: Risks, Controls and Assessment
7 th th Annual National Pharmaceutical Congress November 9, 2006 Off-Label Promotion: Risks, Controls and Assessment John T. Bentivoglio Co-Leader FDA/Healthcare Group jbentivoglio@kslaw.com 202.626.5591
More informationAmerican Academy of Orthopaedic Surgeons 2010 Annual Meeting
American Academy of Orthopaedic Surgeons 2010 Annual Meeting Off-Label Device Use: When Clinical Need Outpaces Regulatory Approval The Legal Parameters of Off-Label Use March 10, 2010 Kathleen McDermott
More informationARNOLD & PORTER UPDATE
ARNOLD & PORTER UPDATE Pharmaceutical Sales and Marketing Practices Government Also Cautions Medical Device Companies on Such Practices April 2003 On April 28, 2003, the Office of Inspector General, Department
More informationToo Much of a Good Thing?
Regulatory s Role in Reviewing External Corporate Communications Too Much of a Good Thing? By John Driscoll Every regulatory professional is a reviewer. One could even say that the majority of our work
More informationPromotion & Advertising of Combination Products: Key Postmarket Considerations
Combination Products Regulation, Policy, & Best Practices It s A Whole New Ballgame Are You All In? June 8, 2017 Promotion & Advertising of Combination Products: Key Postmarket Considerations Moderated
More informationTrends in Pharma Enforcement and Compliance
Pharmaceutical Compliance Forum Trends in Pharma Enforcement and Compliance September 15, 2009 Discussion Topics Key Enforcement Trend: Beyond Sales and Marketing Compliance Trends Oversight and Accountability
More informationTriple C Housing, Inc. Compliance Plan
Triple C Housing, Inc. Compliance Plan Adopted by Board of Directors on draft November 13, 2014 Overview Triple C Housing, Inc. is committed to its consumers, employees, contractual providers, vendors,
More information2/12/2014. Physician Hospital Integration 1. Physician-Hospital Integration Compliance Considerations. Agenda
Physician-Hospital Integration Compliance Considerations Frank E. Sheeder III Chair, Health Care Enforcement and Compliance Practice DLA Piper LLP (US) 214-743-4560 frank.sheeder@dlapiper.com Agenda 1.
More informationMedical Products between
Proactive Communications about Medical Products between Manufacturers and Payors FDLI Advertising & Promotion Conference September 27, 2017 David J. Bloch Principal Legal Counsel, Corporate Legal Regulatory
More informationPresentation Overview
How to Reasonably & Effectively Implement Compliance Programs for Small Group Physician Practices Andrea Merritt, Director of Compliance & Audit Services Ashlie Heald, Compliance Specialist Nova Compliance
More informationSAMPLE COMPLIANCE PLAN. Last revised. Sample only for educational purposes/does not constitute legal advice
SAMPLE COMPLIANCE PLAN Last revised COMPLIANCE PLAN TABLE OF CONTENTS 1. INTRODUCTION... 1 1.1 COMPANYNAME S COMMITMENT TO COMPLIANCE... 1 1.2 BENEFITS OF THE COMPLIANCE PLAN... 1 2. COMPLIANCE WITH LAWS,
More informationRoundtable Webinar. Presenters. April 6, Managed Care Contracting Risks: An Antitrust, Government Pricing and Fraud & Abuse Analysis
Roundtable Webinar Managed Care Contracting Risks: An Antitrust, Government Pricing and Fraud & Abuse Analysis April 6, 2017 Seth Lundy John Shakow John Carroll Presenters Seth Lundy +1 202 626 2924 slundy@kslaw.com
More informationAMETEK, Inc. Code of Ethics and Business Conduct
AMETEK, Inc. Code of Ethics and Business Conduct Code of Ethics and Business Conduct A Message from the Chairman of the Board and Chief Executive Officer Dear AMETEK Colleague: AMETEK has been in business
More informationArc of Onondaga Corporate Compliance Plan
Arc of Onondaga Corporate Compliance Plan The Corporate Compliance Plan consists of eight key elements as well as a wide array of policies and procedures that address key risk areas, to guide our best
More informationBest Buy Political Activity &
Page 1 of 7 A. Policy Overview Purpose: This policy seeks to educate employees on political activity as it pertains to employment with Best Buy as a U.S.-domiciled company. Best Buy encourages employees
More informationA. Establish compliance standards and system-wide policies and procedures;
WellSpan Health Manual of Administrative Policy Page 1 of 10 PURPOSE The WellSpan Health Compliance Program (Program) has been designed, adopted (1999), and implemented as a voluntary program to address
More informationOIG Increases Auditing of Pharmaceutical Manufacturers: Coupons, Part D Remuneration and Medicaid Rebate Administration
For Discussion Purposes Only; Not Intended as Legal Advice. BEIJING BOSTON BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG HOUSTON LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE
More informationAuthor Statements and Copyright Assignment
Author Statements and Copyright Assignment Manuscript title: Corresponding Author: Before your manuscript (the Work ) can be considered for publication in FPM, each author must attest to his or her authorship
More informationAcknowledgement of Aramco Overseas Company BV. Supplier Code of Conduct
IMPORTANT DOCUMENT PLEASE RETURN SIGNED ACKNOWLEDGEMENT Acknowledgement of Aramco Overseas Company BV Supplier Code of Conduct (Applicable to Vendors, Manufacturers, Contractors and Sub-Contractors) Aramco
More informationDelta Dental of Michigan, Ohio, and Indiana. Compliance Plan
Delta Dental of Michigan, Ohio, and Indiana Compliance Plan Procedure #: 420-29 Issue Date: 5/15/2013 Last Revised Date: 5/23/2016 Last Review Date: 5/23/2016 Next Review Date: 5/23/2017 Title: Compliance
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationSHRINERS HOSPITALS FOR CHILDREN CORPORATE COMPLIANCE PLAN
SHRINERS HOSPITALS FOR CHILDREN CORPORATE COMPLIANCE PLAN 1.0 INTRODUCTION Shriners Hospitals for Children ( SHC ) is committed to conducting itself according to applicable business ethical standards and
More informationOPDP Update on Oversight of Prescription Drug Promotion
OPDP Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration November 3, 2014 1 Topics Policy and Guidance Development
More informationPharmaceutical Marketing and Transparency in Japan
International In-house Counsel Journal Vol. 7, No. 25, Autumn 2013, 1 Pharmaceutical Marketing and Transparency in Japan MARIANNE SLIVKOVA, J.D., M.P.H. Senior Corporate Counsel, Bristol-Myers Squibb,
More informationPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationCode of Conduct. 1 P age
Code of Conduct 2013 1 P age Dear Colleagues, At INSYS, we believe in doing the right thing for our patients, customers, employees, communities and business partners. Our patients and customers trust the
More informationMarketing Guidelines for Electronic Retailers
Marketing Guidelines for Electronic Retailers The Electronic Retailing Association ( ERA ) believes that consumer confidence is the key to the continued growth and success of the electronic retailing industry.
More informationYour Guide to the Compliance Process
Your Guide to the Compliance Process Our Commitment and Your Responsibilities Disciplinary Action Guidelines Guidance for Managers Investigations Process Overview US Reporting Process Overview Corporate
More informationCity of Colorado Springs Code of Ethics
City of Colorado Springs Code of Ethics CITY OF COLORADO SPRINGS, COLORADO CODE OF ETHICS As found in Chapter 1, Article 3 of the City Code 1.3.101: LEGISLATIVE PURPOSE: A. There is hereby adopted by the
More informationCORPORATE POLICIES AND PROCEDURES. GIFTS NO.: (Formerly ADM X 260)
CORPORATE POLICIES AND PROCEDURES GIFTS NO.: 00365 (Formerly ADM X 260) ISSUED BY: V.P. Human Resources DATE OF APPROVAL: 2008/10/08 APPROVED BY: Senior Management LAST REVIEW/REVISION DATE: Committee
More informationThe Company seeks to comply with both the letter and spirit of the laws and regulations in all jurisdictions in which it operates.
1. Policy Statement CRC HEALTH GROUP, INC. CRC HEALTH CORPORATION CODE OF BUSINESS CONDUCT AND ETHICS It is the policy of CRC Health Group to conduct its business affairs honestly and in an ethical manner.
More informationTAP AUTOMOTIVE HOLDINGS, LLC TAP WORLDWIDE, LLC / TAP MANUFACTURING, LLC Code of Conduct and Business Ethics
Revised and Reissued August 2015 TAP AUTOMOTIVE HOLDINGS, LLC TAP WORLDWIDE, LLC / TAP MANUFACTURING, LLC Code of Conduct and Business Ethics THIS POLICY DOES NOT CREATE AN EXPRESS OR IMPLIED EMPLOYMENT
More informationLiving Our Purpose and Core Values CODE. Code of Business Ethics and Conduct for Vendors
Living Our Purpose and Core Values CODE Code of Business Ethics and Conduct for Vendors December 2016 HCSC Vendor Code of Business Ethics and Conduct Since 1936, Health Care Service Corporation, a Mutual
More informationCommercial Pricing and Contracting 101
Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai
More informationDisclosure Best Practices Toolkit
Disclosure Best Practices Toolkit Introduction This document is a draft series of checklists to help companies, their employees, and their agencies learn the appropriate and transparent ways to interact
More informationUnderstanding the New Complexities of Clinical Trials from Results Reporting and FMV to Off-label Communication and Aggregate Spend
Understing New Complexities Clinical Trials from Results Reporting FMV Off-label Communication Aggregate Spend Mark DeWyngaert, Ph.D. Kathleen Tench Huron Consulting Group Life Sciences Advisory Services
More informationSUNRISE TELECOM CODE OF BUSINESS CONDUCT AND ETHICS Overview Sunrise Telecom is committed to its customers, partners, employees and stockholders.
SUNRISE TELECOM CODE OF BUSINESS CONDUCT AND ETHICS Overview Sunrise Telecom is committed to its customers, partners, employees and stockholders. Accordingly, we believe that operating with integrity is
More informationARCADIS GENERAL BUSINESS PRINCIPLES. July 2016
ARCADIS GENERAL BUSINESS PRINCIPLES July 2016 ARCADIS GENERAL BUSINESS PRINCIPLES 1. INTRODUCTION At Arcadis we define our mission as: Our mission is to create exceptional and sustainable outcomes for
More informationEMEA Speaker Brief Page 1
EMEA SPEAKER BRIEF Commitment to ethics and integrity Bristol-Myers Squibb (BMS) is committed to the highest standards of ethics and integrity and recognises the high expectations of honesty and transparency
More informationTEEKAY TANKERS LTD. STANDARDS OF BUSINESS CONDUCT POLICY
TEEKAY TANKERS LTD. STANDARDS OF BUSINESS CONDUCT POLICY WHY TEEKAY HAS STANDARDS OF BUSINESS CONDUCT As responsible business leaders, it is not enough to do things right; it is also important to do them
More informationAfter approval, a biotechnology product continues to be subject to regulation
Chapter XVI Legal Requirements After Approval Areta L. Kupchyk, Esq. Reed & Smith, LLP Washington, D.C. After approval, a biotechnology product continues to be subject to regulation in that it must be
More informationCompliance Plans. Kelly S. McIntosh July 20, 2017
Compliance Plans Kelly S. McIntosh July 20, 2017 Roadmap The importance of compliance and compliance programs Common compliance issues know your risk areas! Guidance for drafting or updating your compliance
More informationWELLTOK, INC. CODE OF BUSINESS CONDUCT AND ETHICS As Adopted by the Board of Directors and Audit Committee on May 3, 2016
WELLTOK, INC. CODE OF BUSINESS CONDUCT AND ETHICS As Adopted by the Board of Directors and Audit Committee on May 3, 2016 I. INTRODUCTION Welltok, Inc. ( Welltok and together with its subsidiaries, the
More informationBest Buy Political Activity & Government Relations Policy
Best Buy Political Activity & Government Relations Policy Employee Policy B e s t B u y C o., I n c. G o v e r n m e n t R e l a t i o n s D e p a r t m e n t This policy seeks to educate employees on
More informationJeffrey K. Francer Vice President and Senior Counsel. September 16, 2014
Jeffrey K. Francer Vice President and Senior Counsel September 16, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Draft
More informationHopedale Medical Complex. Document Title: Corporate Compliance Program Document Type: Plan. Owner: Chief Compliance Officer Committee Review:
Page id 25 The purpose and goals of the Program are to: PURPOSE & GOALS program significantly reduces the risk of unlawful improper conduct. waste from HMC, it is believed a sincere effort (via the Program)
More informationCompliance and the Board of Directors
Adam J. Falcone, Esq., Partner Dianne K. Pledgie, Esq., Compliance Counsel Feldesman Tucker Leifer Fidell, LLP Compliance and the Board of Directors Speaker Name Title Organization Disclaimer: EDUCATIONAL
More information2. The name of a private person bringing a civil action in the name of the U.S. is. 3. Medicare Part A pays primarily for.
Intro & Basics of the Law to Antitrust Laws (Possible 12 Continuing Education Units with 75% correct) 1. Name two benefits of a Compliance Program? 2. The name of a private person bringing a civil action
More informationResponsibility Standards for Suppliers
Responsibility Standards for Suppliers 2017 GLOBAL PROCUREMENT Our Credo We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationCode of Business Conduct and Ethics
Code of Business Conduct and Ethics Table of Contents Purpose... 1 Scope... 1 Policy... 2 Responsibilities... 8 Enforcement... 8 Review and Revision... 8 PURPOSE Pursuant to the Sarbanes-Oxley Act of 2002
More informationAdvertising and Marketing Genetic Tests New Pathways or Old Roads?
Advertising and Marketing Genetic Tests New Pathways or Old Roads? Kathleen M. Sanzo, Morgan Lewis FDLI Advertising & Promotion Conference Wednesday, September 28, 2016 Context for Use of Genetic Tests
More informationCode of Business Conduct
Subject CODE OF BUSINESS CONDUCT Section POLICY STATEMENT Sponsor CHIEF LEGAL OFFICER Number Version 1.0 Effective Date: December 2014 Code of Business Conduct Indivior PLC is committed to responsible
More informationBUSINESS ETHICS POLICY and GUIDING PRINCIPLES
BUSINESS ETHICS POLICY and GUIDING PRINCIPLES The Guiding Principles form the core of the culture of Kimball International, and transcends decades. Kimball International is committed to ethical practices
More informationSupplier Code of Conduct
Samsung Telecommunications America, LLC Supplier Code of Conduct - Partners in Integrity STA Strategic SRM 10/1/2013 Rev. C Samsung Telecommunications America, LLC ( STA or Samsung Telecommunications America
More informationCode of Ethical Conduct for Governance Officials 1
1 Principles 1. Ethical conduct is a hallmark of the Global Fund, and applies to all those involved in the operation and governance of the organization. Consequently, those involved in the governance of
More informationTHE DEPARTMENT OF HEALTH AND SENIOR SERVICES CODE OF ETHICS
THE DEPARTMENT OF HEALTH AND SENIOR SERVICES CODE OF ETHICS I. GENERAL PRINCIPLES AND PROCEDURES II. III. IV. REPRESENTATION BEFORE AND CONTRACTS WITH THE STATE POST-EMPLOYMENT RESTRICTIONS ATTENDANCE
More informationSeptember 16, Via Electronic Submission
Via Electronic Submission Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Draft Guidance for Industry: Internet/Social Media Platforms: Correcting
More informationCounty of Ingham State of Michigan
County of Ingham State of Michigan PO Box 319 / 121 E. Maple St. Purchasing Department Mason, Michigan 48854 Phone: (517) 676-7222 http://pu.ingham.org/home.aspx Greetings, Thank you for your interest
More informationDOUBLE-TAKE SOFTWARE, INC. CODE OF BUSINESS CONDUCT AND ETHICS
DOUBLE-TAKE SOFTWARE, INC. CODE OF BUSINESS CONDUCT AND ETHICS This Code of Business Conduct and Ethics covers a wide range of business practices and procedures and serves as a guide to ethical decision-making.
More informationLIVING OUR CORE VALUES. Supplier Code of Conduct
LIVING OUR CORE VALUES Supplier Code of Conduct Introduction to Our Supplier Code of Conduct Chesapeake Energy is committed to living our core values of integrity and trust, respect, transparency and open
More informationSIIA S CORPORATE ANTI-PIRACY REWARD PROGRAM
SIIA S CORPORATE ANTI-PIRACY REWARD PROGRAM The Software & Information Industry Association (SIIA) offers rewards of up to $1,000,000 to individuals who report verifiable corporate end-user piracy to SIIA
More informationMARKETING GUIDELINES FOR ELECTRONIC RETAILERS
MARKETING GUIDELINES FOR ELECTRONIC RETAILERS The Electronic Retailing Association ( ERA ) believes that consumer confidence is the key to the continued growth and success of the electronic retailing industry.
More informationCode of Business Conduct
Code of Business Conduct High Ethical Standards: The Key to Our Success Our Code of Business Conduct is part of our way of life at Blue Cross Blue Shield of Michigan and Blue Care Network. Corporate ethics
More informationAllergan plc COMPREHENSIVE COMPLIANCE PROGRAM
Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign
More informationGlobal Code of Business Conduct
Global Code of Business Conduct 2 of 16 INSIDE THIS CODE Living Our Values, Fulfilling Our Purpose... 3 Why Do We Need this Code?... 4 Using this Code... 4 Our Commitment to Our Values... 5 Our Commitment
More informationBribery and Research Integrity in Foreign Clinical Trials: Practical Strategies for Reducing Your Company s Compliance Risks
November 3, 2011 Bribery and Research Integrity in Foreign Clinical Trials: Practical Strategies for Reducing Your Company s Compliance Risks Sue Sefarian Health Care Compliance Officer Johnson & Johnson
More informationCODE OF ETHICS AND PROFESSIONAL CONDUCT
CODE OF ETHICS AND PROFESSIONAL CONDUCT Preamble Members of The American Institute of Architects are dedicated to the highest standards of professionalism, integrity, and competence. This Code of Ethics
More informationAAD ADVERTISING STANDARDS
Approved: Board of Directors 11/14/09 AAD ADVERTISING STANDARDS The American Academy of Dermatology and AAD Association (collectively, the Academy ) seeks to advance the science and art of dermatology
More informationMaricopa Integrated Health System CODE OF CONDUCT AND ETHICS
Maricopa Integrated Health System CODE OF CONDUCT AND ETHICS March, 2012 March, 2012 Dear Member of the Maricopa Integrated Health System Team: Personal and corporate integrity has been one of Maricopa
More informationWe Maintain Accurate Financial Books and Records. We Strive to Comply with All Laws and Regulations. We Maintain the Confidences Entrusted to Us
Code of Business Conduct and Ethics Contents: 1. Introduction: Philosophy Underlying This Code 2. 10 Principles: principles that establish a framework and provide guidance to all employees on how to ensure
More informationCODE OF CONDUCT AND ETHICS
CODE OF CONDUCT AND ETHICS As revised on November 16, 2017, Approved by the Corporate Compliance Committee on November 17, 2017, and Approved by the Board of Directors on December 11, 2017 A MESSAGE FROM
More informationINTRODUCTION. Overview of Compliance Program. I. Leadership and Structure. GSK Ethics & Compliance Program US Operations
GSK Ethics & Compliance Program US Operations INTRODUCTION GlaxoSmithKline (GSK) is one of the world s leading research-based pharmaceutical and healthcare companies. GSK s global mission is to improve
More informationJPMorgan Chase & Co. Supplier Code of Conduct
JPMorgan Chase & Co. Supplier Code of Conduct Current Effective Date: October 28, 2016 TABLE OF CONTENTS 1. Summary or Rationale... 2 2. Scope... 2 3. Changes from Previous Version... 2 4. Policy Statements...
More informationMODA HEALTH CODE OF CONDUCT
MODA HEALTH CODE OF CONDUCT I. Introduction Moda Health has a longstanding tradition of caring for our members, communities, and employees. We strive to act with absolute integrity in the way we do our
More informationPharmaceutical Compliance Congress: Pricing Update
Pharmaceutical Compliance Congress: Pricing Update November 3, 2011 Jeffrey L. Handwerker Agenda Medicaid Drug Rebate Program OIG Work Plan Draft FULs AMP vs. ASP Comparisons NADAC Survey 340B Program
More informationSTUDY UNIT TEN INTERNAL AUDIT RESPONSIBILITIES FOR FRAUD
STUDY UNIT TEN INTERNAL AUDIT RESPONSIBILITIES FOR FRAUD 1 10.1 Fraud -- Nature, Prevention, and Detection..................................... 1 10.2 Fraud -- Indicators........................................................
More informationMount Sinai Health Partners and Initiatives Compliance Education
Mount Sinai Health Partners and Initiatives Compliance Education 2016 Audit and Compliance Services (ACS) Introduction 3 Welcome to the MSHP Compliance Education program The following presentation reviews
More informationTHE E-VERIFY PROGRAM FOR EMPLOYMENT VERIFICATION MEMORANDUM OF UNDERSTANDING ARTICLE I PURPOSE AND AUTHORITY
THE E-VERIFY PROGRAM FOR EMPLOYMENT VERIFICATION MEMORANDUM OF UNDERSTANDING ARTICLE I PURPOSE AND AUTHORITY This Memorandum of Understanding (MOU) sets forth the points of agreement between the Department
More informationMEASURING & MONITORING RISK USING ANALYTICS
MEASURING & MONITORING RISK USING ANALYTICS APRIL 13, 2017 2017 HURON CONSULTING GROUP INC. PRESENTERS Brian Bohnenkamp Partner King & Spalding BBohnenkamp@KSLAW.com Jack Tanselle Managing Director Huron
More informationSalt Lake Community College Ethics - Conduct and Policy. What Employees Need to Know
Salt Lake Community College Ethics - Conduct and Policy What Employees Need to Know Applicable Laws-Utah Code 53B-3-103 - Power of Board to adopt rules and enact regulations. The board may enact regulations
More informationFOUNDATION BUILDING MATERIALS, INC. EMPLOYEE CODE OF CONDUCT
FOUNDATION BUILDING MATERIALS, INC. EMPLOYEE CODE OF CONDUCT Foundation Building Materials, Inc. (the Company ) conducts its business in accordance with the highest ethical standards of corporate leadership
More informationLOS ANGELES UNIFIED SCHOOL DISTRICT POLICY BULLETIN
TITLE: NUMBER: Reasonable Accommodation for Individuals with Disabilities BUL-4569.0 ROUTING All Employees All Locations ISSUER: David Holmquist, Chief Operating Officer Roberta Fesler, General Counsel
More informationPT Solutions Holdings, LLC COMPLIANCE PLAN. The Basis of Our Success
PT Solutions Holdings, LLC COMPLIANCE PLAN The Basis of Our Success July 1, 2012 GENERAL OVERVIEW The Office of the Inspector General ( OIG ) has indicated that an effective compliance plan should contain
More informationOntario ARC Corporate Compliance. Policies and Procedures Manual
Ontario ARC Corporate Compliance Policies and Procedures Manual To Report a Corporate Compliance violation: 1 2. 3. Contact your supervisor; or Contact a Corporate Compliance Committee member. If you are
More informationHelping Pharmas Manage Compliance Risks for Speaker Programs
COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively
More informationPrivacy Policy PURPOSE SCOPE POLICY. Data Collection
Privacy Policy PURPOSE 1. To ensure Training & Assessment Mentor maintains the privacy of personal information provided to Training & Assessment Mentor from Staff and Students. SCOPE 2. This document describes
More informationBUSINESS PRINCIPLES FOR PROMOTING INTEGRITY IN THE PHARMACEUTICAL SECTOR
BUSINESS PRINCIPLES FOR PROMOTING INTEGRITY IN THE PHARMACEUTICAL SECTOR A REGIONAL MULTI-STAKEHOLDER INITIATIVE FOR LATIN AMERICA LED BY TRANSPARENCY INTERNATIONAL UK S PHARMACEUTICALS & HEALTHCARE PROGRAMME
More informationMinistry-wide Setting: Organization-wide Areas/Dept: All Title: Conflict of Interest and Disclosure Process (CC-701) Category/Chapter: Compliance
Ministry-wide Setting: Organization-wide Areas/Dept: All Title: Conflict of Interest and Disclosure Process (CC-701) Category/Chapter: Compliance DEFINITIONS: 1. A Conflict of Interest occurs when an OSF
More informationBJC HealthCare c o d e o f c o n d u c t
BJC HealthCare c o d e o f c o n d u c t 1 2 Table of Contents BJC HealthCare Purpose, Goal and Shared Principles..................... 1 The BJC Compliance Program...........................................
More informationSOUTH DAKOTA BOARD OF REGENTS. Policy Manual
SUBJECT: Conflict of Interest NUMBER: 4:35 SOUTH DAKOTA BOARD OF REGENTS Policy Manual 1. Persons employed full-time by the South Dakota Board of Regents in professional capacities, whether as faculty
More informationUnder this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at
DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory
More informationATI Application for Employment
ATI is committed to the principle of equal employment opportunity for all employees with a work environment free of discrimination and harassment. All employment decisions at ATI are based on business
More informationMid-America Intergovernmental Audit Forum. Selecting an External Auditor. Guide for Making a Sound Decision
Mid-America Intergovernmental Audit Forum Selecting an External Auditor Guide for Making a Sound Decision May 2007 Foreword The benefits of having a high-quality audit of a government's financial statements
More informationCITY OF WEST HOLLYWOOD
CITY OF WEST HOLLYWOOD CODE OF CONDUCT FOR ELECTED AND APPOINTED OFFICIALS 1. Introduction The purpose of this Code of Conduct ( Code ) is to define the role of elected and appointed officials (members
More informationOtsuka. Supporting. Supplier Code of Ethics and Professional Conduct
Supporting Otsuka Supplier Code of Ethics and Professional Conduct Otsuka America Pharmaceutical, Inc. (OAPI) Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Otsuka Maryland Medicinal
More informationVOLUNTEERS OF AMERICA GREATER NEW YORK
VOLUNTEERS OF AMERICA GREATER NEW YORK I. PURPOSE Code of Conduct: Organization Compliance Plan Reviewed: May 24, 2017 The Code of Conduct ( The Code ), which serves as Volunteers of America- Greater New
More informationCITY OF PALO ALTO COUNCIL PROTOCOLS
CITY OF PALO ALTO COUNCIL PROTOCOLS All Council Members All members of the City Council, including those serving as Mayor and Vice Mayor, have equal votes. No Council Member has more power than any other
More informationCONFLICT OF INTEREST STATEMENT AND DISCLOSURE
CONFLICT OF INTEREST STATEMENT AND DISCLOSURE This statement is a summary of the Boyd Gaming Code of Business Conduct and Ethics and the Boyd Gaming policy regarding fraternization. For a complete version
More information